Research graph
References from Nanoformulations for Ocular Drug Delivery in Glaucoma: From Metal-Based Nanoparticles to Advanced Nanocarriers. Local targets link to admitted publications; unresolved targets remain external evidence.
The Pathophysiology and Treatment of Glaucoma: A Review
10.1001/jama.2014.3192 · 2014 · External reference
Glaucoma
10.1016/s0140-6736(17)31469-1 · 2017 · External reference
Addressing Neurodegeneration in Glaucoma: Mechanisms, Challenges, and Treatments
10.1016/j.preteyeres.2024.101261 · 2024 · External reference
10.3390/ijms252212400
10.3390/ijms252212400 · External reference
Global Prevalence of Glaucoma and Projections of Glaucoma Burden through 2040: A Systematic Review and Meta-Analysis
10.1016/j.ophtha.2014.05.013 · 2014 · External reference
Global Causes of Blindness and Distance Vision Impairment 1990–2020: A Systematic Review and Meta-Analysis
10.1016/s2214-109x(17)30393-5 · 2017 · External reference
Unresolved reference
External reference
Critical Pathogenic Events Underlying Progression of Neurodegeneration in Glaucoma
10.1016/j.preteyeres.2012.07.001 · 2012 · External reference
Neuroprotection for Glaucoma: Requirements for Clinical Translation
10.1016/j.exer.2016.12.005 · 2017 · External reference
Ocular Drug Delivery: A Comprehensive Review
10.1208/s12249-023-02516-9 · 2023 · External reference
Unresolved reference
External reference
10.3390/gels8020082
10.3390/gels8020082 · External reference
Nanotechnology for Medical and Surgical Glaucoma Therapy—A Review
10.1007/s12325-019-01163-6 · 2020 · External reference
Nanomedicines for the Treatment of Glaucoma: Current Status and Future Perspectives
10.1016/j.actbio.2021.02.017 · 2021 · External reference
10.3390/pharmaceutics17081087
10.3390/pharmaceutics17081087 · External reference
10.3390/polym15061373
10.3390/polym15061373 · External reference
Innovative Applications of Nanomaterials in the Diagnosis and Treatment of Ocular Diseases: Targeted Delivery, Intelligent Therapy, Diagnostic Breakthroughs, and Synergistic Strategies with Stem Cells and Biomaterials
10.2147/ijn.s577320 · 2026 · External reference
10.3390/molecules28186687
10.3390/molecules28186687 · External reference
Engineered Superparamagnetic Mn0.5Zn0.5Fe2O4 Nanoparticles as a Heat Shock Protein Induction Agent for Ocular Neuroprotection in Glaucoma
10.1016/j.biomaterials.2010.09.016 · 2011 · External reference
Copper Oxide Nanoparticles: In Vitro and in Vivo Toxicity, Mechanisms of Action and Factors Influencing Their Toxicology
10.1016/j.cbpc.2023.109682 · 2023 · External reference
10.3390/bioengineering9010041
10.3390/bioengineering9010041 · External reference
Synthesis of Silver Nanoparticles by Using Aloe vera and Thuja orientalis Leaves Extract and Their Biological Activity: A Comprehensive Review
10.1186/s42269-021-00639-2 · 2021 · External reference
Dual-Functional Nanoparticle Formulations for Simultaneous Intraocular Pressure Reduction and Neuroprotection in Glaucoma: A Review
10.1080/17435889.2025.2608944 · 2026 · External reference
Oxidative Stress and Potential Applications of Free Radical Scavengers in Glaucoma
10.1179/1351000212y.0000000033 · 2013 · External reference
Nicotinamide Provides Neuroprotection in Glaucoma by Protecting against Mitochondrial and Metabolic Dysfunction
10.1016/j.redox.2021.101988 · 2021 · External reference
Differences and Similarities Between Primary Open Angle Glaucoma and Primary Angle-Closure Glaucoma
10.2147/eb.s472920 · 2024 · External reference
European Glaucoma Society Terminology and Guidelines for Glaucoma, 5th Edition
2021 · External reference
Rho-Kinase Inhibitors as Emerging Targets for Glaucoma Therapy
10.1007/s40123-023-00820-y · 2023 · External reference
Impact of the clinical use of ROCK inhibitor on the pathogenesis and treatment of glaucoma
10.1007/s10384-018-0566-9 · 2018 · External reference
Discovery and preclinical development of netarsudil, a novel ocular hypotensive agent for the treatment of glaucoma
10.1089/jop.2017.0023 · 2018 · External reference
Exploring a Novel Fasudil-Phospholipid Complex Formulated as Liposomal Thermosensitive in Situ Gel for Glaucoma
10.2147/ijn.s342975 · 2022 · External reference
Sustained Latanoprost Release from PEGylated Solid Lipid Nanoparticle-Laden Soft Contact Lens to Treat Glaucoma
10.1080/10837450.2021.1999471 · 2022 · External reference
Improvement in Inner Retinal Function in Glaucoma with Nicotinamide (Vitamin B3) Supplementation: A Crossover Randomized Clinical Trial
10.1111/ceo.13818 · 2020 · External reference
Poly(2-ethyl-2-oxazoline)-coated solid lipid nanoparticles to enhance ocular delivery of timolol maleate: Design, fabrication and in vitro-in vivo evaluations
10.1016/j.jddst.2026.108167 · 2026 · External reference
Targeted Microglial Attenuation through Dendrimer–Drug Conjugates Improves Glaucoma Neuroprotection
10.1021/acs.biomac.2c01381 · 2023 · External reference
Research Progress of Nano Delivery Systems for Intraocular Pressure Lowering Drugs
10.1016/j.heliyon.2024.e32602 · 2024 · External reference
Recent Advances in Nanocrystal-Based Technologies Applied for Ocular Drug Delivery
10.1080/17425247.2024.2311119 · 2024 · External reference
Doctor-Patient Communication, Health-Related Beliefs, and Adherence in Glaucoma Results from the Glaucoma Adherence and Persistency Study
10.1016/j.ophtha.2007.11.023 · 2008 · External reference
Systemic side effects of eye drops: A pharmacokinetic perspective
10.2147/opth.s118409 · 2016 · External reference
10.3390/pharmaceutics14091931
10.3390/pharmaceutics14091931 · External reference
There’s danger in the drops: Systemic effects of ophthalmic drops used to treat glaucoma
2022 · External reference
Efficacy and safety of a preservative-free latanoprost cationic emulsion in patients with open-angle glaucoma and concurrent ocular surface disease: A randomized phase 2 study
10.1089/jop.2024.0029 · 2024 · External reference
A phase III study comparing preservative-free latanoprost eye drop emulsion with preserved latanoprost in open-angle glaucoma or ocular hypertension
10.1038/s41433-025-03646-z · 2025 · External reference
Recent updates on ocular disease management with ophthalmic ointments
10.1080/20415990.2024.2346047 · 2024 · External reference
Ophthalmic Nanoemulsions: From Composition to Technological Processes and Quality Control
10.1021/acs.molpharmaceut.1c00650 · 2021 · External reference
Toxicity of nanomaterials to the eye
10.1002/wnan.65 · 2010 · External reference
Sustained bimatoprost release using gold nanoparticles laden contact lenses
10.1080/09205063.2021.1927656 · 2021 · External reference
Morphologic design of nanogold carriers for a carbonic anhydrase inhibitor: Effect on ocular retention and intraocular pressure
10.1016/j.ijpharm.2023.123161 · 2023 · External reference
Effects of gold nanoparticles on endotoxin-induced uveitis in rats
10.1167/iovs.12-10743 · 2012 · External reference
Effect of gold nanoparticles on timolol uptake and its release kinetics from contact lenses: In vitro and in vivo evaluation
10.1016/j.actbio.2019.01.004 · 2019 · External reference
10.3390/pharmaceutics13060901
10.3390/pharmaceutics13060901 · External reference
Hyaluronic acid coating of gold nanoparticles for intraocular drug delivery: Evaluation of the surface properties and effect on their distribution
10.1016/j.exer.2020.108151 · 2020 · External reference
Emerging Drug Delivery Strategies for Glaucoma Therapy: Focus on Nanoparticles and Stimuli-Responsive Systems
10.1039/d5pm00068h · 2025 · External reference
Protein-Based Silver Nanoparticles: Synthesis, Characterization, Administration, and Nanomedicine Applications
10.1155/ijbm/5533798 · 2025 · External reference
Metal-organic frameworks as drug delivery platforms for ocular therapeutics
10.1021/acsami.8b20222 · 2019 · External reference
10.3390/nano12020277
10.3390/nano12020277 · External reference
Metal-organic frameworks, NH2-MIL-88(Fe), as carriers for ophthalmic delivery of brimonidine
10.1016/j.actbio.2018.08.023 · 2018 · External reference
10.3390/pharmaceutics15061593
10.3390/pharmaceutics15061593 · External reference
Liposomal Topical Drug Administration Surpasses Alternative Methods in Glaucoma Therapeutics: A Novel Paradigm for Enhanced Treatment
10.1093/jpp/rgae129 · 2025 · External reference
Nanomedicine for glaucoma: Liposomes provide sustained release of latanoprost in the eye
2012 · External reference
Treatment merits of latanoprost/thymoquinone-encapsulated liposome for glaucomatous rabbits
10.1016/j.ijpharm.2018.07.012 · 2018 · External reference
10.3390/nano14161347
10.3390/nano14161347 · External reference
10.1186/s12868-025-00971-7
10.1186/s12868-025-00971-7 · External reference
Dendrimers: A Versatile Nanocarrier for Drug Delivery and Targeting
10.1016/j.ijpharm.2018.07.030 · 2018 · External reference
Nano-in-Nano Dendrimer Gel Particles for Efficient Topical Delivery of Antiglaucoma Drugs into the Eye
10.1016/j.cej.2021.130498 · 2021 · External reference
Dendrimer-Triamcinolone Acetonide Reduces Neuroinflammation, Pathological Angiogenesis, and Neuroretinal Dysfunction in Ischemic Retinopathy
10.1002/adtp.202000181 · 2021 · External reference
10.3390/pharmaceutics16070903
10.3390/pharmaceutics16070903 · External reference
γ-Cyclodextrin nanoparticle eye drops with dorzolamide: Effect on intraocular pressure in man
10.1089/jop.2013.0060 · 2014 · External reference
New prostaglandin analog formulation for glaucoma treatment containing cyclodextrins for improved stability, solubility and ocular tolerance
10.1016/j.ejpb.2015.04.032 · 2015 · External reference
10.3390/gels8080510
10.3390/gels8080510 · External reference
Extended Levobunolol Release from Eudragit Nanoparticle-Laden Contact Lenses for Glaucoma Therapy
10.1186/s43094-020-00128-9 · 2020 · External reference
Nanoparticle-Loaded Hydrogels as a Pathway for Enzyme-Triggered Drug Release in Ophthalmic Applications
10.1016/j.ijpharm.2017.11.053 · 2018 · External reference
10.3390/ph17091190
10.3390/ph17091190 · External reference
Current Situation and Progress of Drugs for Reducing Intraocular Pressure
10.1177/20406223221140392 · 2022 · External reference
Nanomedicine in Glaucoma Treatment; Current Challenges and Future Perspectives
10.1016/j.mtbio.2024.101229 · 2024 · External reference
Applying Nanotechnology to Glaucoma Therapy: Past, Present, and Future
10.1080/17435889.2025.2497748 · 2025 · External reference
10.3390/pharmaceutics18030282
10.3390/pharmaceutics18030282 · External reference
The Pathophysiology and Treatment of Glaucoma: A Review
10.1001/jama.2014.3192 · ExternalCitation · doi-reference
Dendrimer-Triamcinolone Acetonide Reduces Neuroinflammation, Pathological Angiogenesis, and Neuroretinal Dysfunction in Ischemic Retinopathy
10.1002/adtp.202000181 · ExternalCitation · doi-reference
Toxicity of nanomaterials to the eye
10.1002/wnan.65 · ExternalCitation · doi-reference
Impact of the clinical use of ROCK inhibitor on the pathogenesis and treatment of glaucoma
10.1007/s10384-018-0566-9 · ExternalCitation · doi-reference
Nanotechnology for Medical and Surgical Glaucoma Therapy—A Review
10.1007/s12325-019-01163-6 · ExternalCitation · doi-reference
Rho-Kinase Inhibitors as Emerging Targets for Glaucoma Therapy
10.1007/s40123-023-00820-y · ExternalCitation · doi-reference
Metal-organic frameworks, NH2-MIL-88(Fe), as carriers for ophthalmic delivery of brimonidine
10.1016/j.actbio.2018.08.023 · ExternalCitation · doi-reference
Effect of gold nanoparticles on timolol uptake and its release kinetics from contact lenses: In vitro and in vivo evaluation
10.1016/j.actbio.2019.01.004 · ExternalCitation · doi-reference
Nanomedicines for the Treatment of Glaucoma: Current Status and Future Perspectives
10.1016/j.actbio.2021.02.017 · ExternalCitation · doi-reference
Engineered Superparamagnetic Mn0.5Zn0.5Fe2O4 Nanoparticles as a Heat Shock Protein Induction Agent for Ocular Neuroprotection in Glaucoma
10.1016/j.biomaterials.2010.09.016 · ExternalCitation · doi-reference
Copper Oxide Nanoparticles: In Vitro and in Vivo Toxicity, Mechanisms of Action and Factors Influencing Their Toxicology
10.1016/j.cbpc.2023.109682 · ExternalCitation · doi-reference
Nano-in-Nano Dendrimer Gel Particles for Efficient Topical Delivery of Antiglaucoma Drugs into the Eye
10.1016/j.cej.2021.130498 · ExternalCitation · doi-reference
New prostaglandin analog formulation for glaucoma treatment containing cyclodextrins for improved stability, solubility and ocular tolerance
10.1016/j.ejpb.2015.04.032 · ExternalCitation · doi-reference
Neuroprotection for Glaucoma: Requirements for Clinical Translation
10.1016/j.exer.2016.12.005 · ExternalCitation · doi-reference
Hyaluronic acid coating of gold nanoparticles for intraocular drug delivery: Evaluation of the surface properties and effect on their distribution
10.1016/j.exer.2020.108151 · ExternalCitation · doi-reference
Research Progress of Nano Delivery Systems for Intraocular Pressure Lowering Drugs
10.1016/j.heliyon.2024.e32602 · ExternalCitation · doi-reference
Nanoparticle-Loaded Hydrogels as a Pathway for Enzyme-Triggered Drug Release in Ophthalmic Applications
10.1016/j.ijpharm.2017.11.053 · ExternalCitation · doi-reference
Treatment merits of latanoprost/thymoquinone-encapsulated liposome for glaucomatous rabbits
10.1016/j.ijpharm.2018.07.012 · ExternalCitation · doi-reference
Dendrimers: A Versatile Nanocarrier for Drug Delivery and Targeting
10.1016/j.ijpharm.2018.07.030 · ExternalCitation · doi-reference
Morphologic design of nanogold carriers for a carbonic anhydrase inhibitor: Effect on ocular retention and intraocular pressure
10.1016/j.ijpharm.2023.123161 · ExternalCitation · doi-reference
Poly(2-ethyl-2-oxazoline)-coated solid lipid nanoparticles to enhance ocular delivery of timolol maleate: Design, fabrication and in vitro-in vivo evaluations
10.1016/j.jddst.2026.108167 · ExternalCitation · doi-reference
Nanomedicine in Glaucoma Treatment; Current Challenges and Future Perspectives
10.1016/j.mtbio.2024.101229 · ExternalCitation · doi-reference
Doctor-Patient Communication, Health-Related Beliefs, and Adherence in Glaucoma Results from the Glaucoma Adherence and Persistency Study
10.1016/j.ophtha.2007.11.023 · ExternalCitation · doi-reference
Global Prevalence of Glaucoma and Projections of Glaucoma Burden through 2040: A Systematic Review and Meta-Analysis
10.1016/j.ophtha.2014.05.013 · ExternalCitation · doi-reference
Critical Pathogenic Events Underlying Progression of Neurodegeneration in Glaucoma
10.1016/j.preteyeres.2012.07.001 · ExternalCitation · doi-reference
Addressing Neurodegeneration in Glaucoma: Mechanisms, Challenges, and Treatments
10.1016/j.preteyeres.2024.101261 · ExternalCitation · doi-reference
Nicotinamide Provides Neuroprotection in Glaucoma by Protecting against Mitochondrial and Metabolic Dysfunction
10.1016/j.redox.2021.101988 · ExternalCitation · doi-reference
Glaucoma
10.1016/s0140-6736(17)31469-1 · ExternalCitation · doi-reference
Global Causes of Blindness and Distance Vision Impairment 1990–2020: A Systematic Review and Meta-Analysis
10.1016/s2214-109x(17)30393-5 · ExternalCitation · doi-reference
Targeted Microglial Attenuation through Dendrimer–Drug Conjugates Improves Glaucoma Neuroprotection
10.1021/acs.biomac.2c01381 · ExternalCitation · doi-reference
Ophthalmic Nanoemulsions: From Composition to Technological Processes and Quality Control
10.1021/acs.molpharmaceut.1c00650 · ExternalCitation · doi-reference
Metal-organic frameworks as drug delivery platforms for ocular therapeutics
10.1021/acsami.8b20222 · ExternalCitation · doi-reference
A phase III study comparing preservative-free latanoprost eye drop emulsion with preserved latanoprost in open-angle glaucoma or ocular hypertension
10.1038/s41433-025-03646-z · ExternalCitation · doi-reference
Emerging Drug Delivery Strategies for Glaucoma Therapy: Focus on Nanoparticles and Stimuli-Responsive Systems
10.1039/d5pm00068h · ExternalCitation · doi-reference
Sustained bimatoprost release using gold nanoparticles laden contact lenses
10.1080/09205063.2021.1927656 · ExternalCitation · doi-reference
Sustained Latanoprost Release from PEGylated Solid Lipid Nanoparticle-Laden Soft Contact Lens to Treat Glaucoma
10.1080/10837450.2021.1999471 · ExternalCitation · doi-reference
Recent Advances in Nanocrystal-Based Technologies Applied for Ocular Drug Delivery
10.1080/17425247.2024.2311119 · ExternalCitation · doi-reference
Applying Nanotechnology to Glaucoma Therapy: Past, Present, and Future
10.1080/17435889.2025.2497748 · ExternalCitation · doi-reference
Dual-Functional Nanoparticle Formulations for Simultaneous Intraocular Pressure Reduction and Neuroprotection in Glaucoma: A Review
10.1080/17435889.2025.2608944 · ExternalCitation · doi-reference
Recent updates on ocular disease management with ophthalmic ointments
10.1080/20415990.2024.2346047 · ExternalCitation · doi-reference
γ-Cyclodextrin nanoparticle eye drops with dorzolamide: Effect on intraocular pressure in man
10.1089/jop.2013.0060 · ExternalCitation · doi-reference
Discovery and preclinical development of netarsudil, a novel ocular hypotensive agent for the treatment of glaucoma
10.1089/jop.2017.0023 · ExternalCitation · doi-reference
Efficacy and safety of a preservative-free latanoprost cationic emulsion in patients with open-angle glaucoma and concurrent ocular surface disease: A randomized phase 2 study
10.1089/jop.2024.0029 · ExternalCitation · doi-reference
Liposomal Topical Drug Administration Surpasses Alternative Methods in Glaucoma Therapeutics: A Novel Paradigm for Enhanced Treatment
10.1093/jpp/rgae129 · ExternalCitation · doi-reference
Improvement in Inner Retinal Function in Glaucoma with Nicotinamide (Vitamin B3) Supplementation: A Crossover Randomized Clinical Trial
10.1111/ceo.13818 · ExternalCitation · doi-reference
Protein-Based Silver Nanoparticles: Synthesis, Characterization, Administration, and Nanomedicine Applications
10.1155/ijbm/5533798 · ExternalCitation · doi-reference
Effects of gold nanoparticles on endotoxin-induced uveitis in rats
10.1167/iovs.12-10743 · ExternalCitation · doi-reference
Current Situation and Progress of Drugs for Reducing Intraocular Pressure
10.1177/20406223221140392 · ExternalCitation · doi-reference
Oxidative Stress and Potential Applications of Free Radical Scavengers in Glaucoma
10.1179/1351000212y.0000000033 · ExternalCitation · doi-reference
10.1186/s12868-025-00971-7
10.1186/s12868-025-00971-7 · ExternalCitation · doi-reference
Synthesis of Silver Nanoparticles by Using Aloe vera and Thuja orientalis Leaves Extract and Their Biological Activity: A Comprehensive Review
10.1186/s42269-021-00639-2 · ExternalCitation · doi-reference
Extended Levobunolol Release from Eudragit Nanoparticle-Laden Contact Lenses for Glaucoma Therapy
10.1186/s43094-020-00128-9 · ExternalCitation · doi-reference
Ocular Drug Delivery: A Comprehensive Review
10.1208/s12249-023-02516-9 · ExternalCitation · doi-reference
Differences and Similarities Between Primary Open Angle Glaucoma and Primary Angle-Closure Glaucoma
10.2147/eb.s472920 · ExternalCitation · doi-reference
Exploring a Novel Fasudil-Phospholipid Complex Formulated as Liposomal Thermosensitive in Situ Gel for Glaucoma
10.2147/ijn.s342975 · ExternalCitation · doi-reference
Innovative Applications of Nanomaterials in the Diagnosis and Treatment of Ocular Diseases: Targeted Delivery, Intelligent Therapy, Diagnostic Breakthroughs, and Synergistic Strategies with Stem Cells and Biomaterials
10.2147/ijn.s577320 · ExternalCitation · doi-reference
Systemic side effects of eye drops: A pharmacokinetic perspective
10.2147/opth.s118409 · ExternalCitation · doi-reference
10.3390/bioengineering9010041
10.3390/bioengineering9010041 · ExternalCitation · doi-reference
10.3390/gels8020082
10.3390/gels8020082 · ExternalCitation · doi-reference
10.3390/gels8080510
10.3390/gels8080510 · ExternalCitation · doi-reference
10.3390/ijms252212400
10.3390/ijms252212400 · ExternalCitation · doi-reference
10.3390/molecules28186687
10.3390/molecules28186687 · ExternalCitation · doi-reference
10.3390/nano12020277
10.3390/nano12020277 · ExternalCitation · doi-reference
10.3390/nano14161347
10.3390/nano14161347 · ExternalCitation · doi-reference
10.3390/ph17091190
10.3390/ph17091190 · ExternalCitation · doi-reference
10.3390/pharmaceutics13060901
10.3390/pharmaceutics13060901 · ExternalCitation · doi-reference
10.3390/pharmaceutics14091931
10.3390/pharmaceutics14091931 · ExternalCitation · doi-reference
10.3390/pharmaceutics15061593
10.3390/pharmaceutics15061593 · ExternalCitation · doi-reference
10.3390/pharmaceutics16070903
10.3390/pharmaceutics16070903 · ExternalCitation · doi-reference
10.3390/pharmaceutics17081087
10.3390/pharmaceutics17081087 · ExternalCitation · doi-reference
10.3390/pharmaceutics18030282
10.3390/pharmaceutics18030282 · ExternalCitation · doi-reference
10.3390/polym15061373
10.3390/polym15061373 · ExternalCitation · doi-reference
